A systematic SPR study of human plasma protein adsorption behavior on the controlled surface packing of self-assembled poly(ethylene oxide) triblock copolymer surfaces.
A well-controlled biocompatible nonfouling surface is significant for biomedical requirements, especially for the improvement of biocompatibility. We demonstrate the low or nonbiofouling surfaces by coating hydrophobic-hydrophilic triblock copolymers of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) on the CH(3)-terminated self-assembled monolayer (SAM). Two types of copolymers are used to modify the surface, one with different PEO/PPO ratios ( approximately 20/80, 40/60, and 80/20, w/w) but the same PPO molecular weight ( approximately 2 k), the other with different copolymer MWs ( approximately 9, 11, and 15 k) but the same PEO/PPO ratio (80/20, w/w). In situ surface plasmon resonance (SPR) sensor is used to evaluate polymer adsorption on the SAMs and subsequent protein adsorption on the copolymer-treated surface. The effects of PEO-PPO-PEO molecular weight, PPO-to-PEO ratio, and ionic strength on protein adsorption from single protein solutions of fibrinogen, BSA, and complex mixed proteins are systematically investigated. A Pluronic F108 treated surface is highly resistant to nonspecific protein adsorption under the optimized conditions (MW of 15 k and PEO/PPO ratio of 80/20). This work demonstrates that the PEO-PPO-PEO polymer is able to achieve ultra low fouling surface via surface modification by controlling surface packing density of polymers (molecular weight, hydrophobic/hydrophilic ratio, and hydrophilic group coverage).
Chang
Yung
Y
Department of Chemical Engineering, Chung Yuan Christian University, Jhong-Li, Taoyuan 320, Taiwan. ychang@cycu.edu.tw
Chu
Wan-Ling
WL
Chen
Wen-Yih
WY
Zheng
Jie
J
Liu
Lingyun
L
Ruaan
Ruoh-Chyu
RC
Higuchi
Akon
A
D000327:Adsorption / Q000187:drug effects; D000818:Animals; D057219:Biofouling; D001798:Blood Proteins / Q000378:metabolism*; D002417:Cattle; D006801:Humans; D008970:Molecular Weight; D020442:Poloxamer / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011409:Propylene Glycols / Q000494:pharmacology*; D012710:Serum Albumin, Bovine / Q000378:metabolism; D020349:Surface Plasmon Resonance / Q000379:methods*; D013499:Surface Properties / Q000187:drug effects
D001798:Blood Proteins; C116176:PEO-PPO-PEO; D011409:Propylene Glycols; D020442:Poloxamer; D012710:Serum Albumin, Bovine; D011092:Polyethylene Glycols